rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2019-618-625rsp-2796Research ArticleМЕЖДУНАРОДНЫЕ И РОССИЙСКИЕ РЕКОМЕНДАЦИИ ПО ЛЕЧЕНИЮ РЕВМАТИЧЕСКИХ ЗАБОЛЕВАНИЙINTERNATIONAL AND RUSSIAN GUIDELINES FOR THE TREATMENT OF RHEUMATIC DISEASESВакцинация в ревматологии - 2019 (по материалам рекомендаций EULAR)Vaccination in rheumatology (the 2019 update of EULAR recommendations)БеловБ. С.BelovB. S.

Борис Сергеевич Белов.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

belovbor@yandex.ruТарасоваГ. М.TarasovaG. M.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

МуравьеваН. В.MuravyevаN. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ФГБНУ Научно-исследовательский институт ревматологии им. В.А. НасоновойРоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation201918122019576618625Copyright © Белов Б.С., Тарасова Г.М., Муравьева Н.В., 20192019Белов Б.С., Тарасова Г.М., Муравьева Н.В.Belov B.S., Tarasova G.M., Muravyevа N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2796

В современной ревматологии коморбидные инфекции оказывают значительное влияние на морбидность и летальность, особенно при иммуновоспалительных ревматических заболеваниях (ИВРЗ). Одним из путей решения указанной проблемы является изучение и активное применение различных вакцин. В настоящей статье проанализирован обновленный вариант рекомендаций по вакцинации взрослых больных ИВРЗ, предложенный в 2019 г. экспертами Европейской антиревматической лиги (EULAR). Обсуждаются безопасность и иммуногенность вакцинации, связанной с предупреждением различных инфекций у больных ИВРЗ. Обозначены основные направления будущих исследований по рассматриваемой проблеме.

In modern rheumatology, comorbid infections have a significant impact on morbidity and mortality, especially in immuneinflammatory rheumatic diseases (IRDs). One of the ways to solve this problem is to study and actively use various vaccines. This paper analyzes the 2019 updated version of the European League Against Rheumatism (EULAR) recommendations for vaccination in adult patients with IRDs. It discusses the safety and immunogenicity of vaccination associated with the prevention of various infections in patients with IRDs. The basic directions of future investigations on this problem are outlined.

аутоиммунные воспалительные ревматические заболеваниягрипппневмониявирус папилломы человекажелтая лихорадкавакцинациярекомендацииimmuneinflammatory rheumatic diseasesinfluenzapneumoniahuman papillomavirusyellow fevervaccinationrecommendationsReferencesБуханова ДВ, Белов БС, Тарасова ГМ и др. Коморбидные инфекции при ревматических заболеваниях (по данным ФГБНУ НИИР им. В.А. Насоновой). Медицинский совет. 2019;(9):86-91 doi: 10.21518/2079-701X-2019-9-86-91Buhanova DV, Belov BS, Tarasova GM, et al. Comorbid infections in rheumatic diseases (according to FSBI V.A. Nasonova RIR). Meditsinsky Sovet. 2019;(9):86-91 (In Russ.). doi: 10.21518/2079-701X-2019-9-86-91Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2019 Aug 14. doi: 10.1136/annrheumdis-2019-215882Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2019 Aug 14. doi: 10.1136/annrheumdis-2019-215882Nguyen M, Lindegaard H, Hendricks O, Friis-MоUer N. Factors associated with influenza and pneumococcal vaccine uptake among rheumatoid arthritis patients in Denmark invited to participate in a pneumococcal vaccine trial (Immunovax_RA). Scand J Rheumatol. 2017 Nov;46(6):446-53. doi: 10.1080/03009742.2016.1242774Nguyen M, Lindegaard H, Hendricks O, Friis-MоUer N. Factors associated with influenza and pneumococcal vaccine uptake among rheumatoid arthritis patients in Denmark invited to participate in a pneumococcal vaccine trial (Immunovax_RA). Scand J Rheumatol. 2017 Nov;46(6):446-53. doi: 10.1080/03009742.2016.1242774Loubet P, Kerneis S, Groh M, et al. Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency. Vaccine. 2015;33(31):3703-8. doi: 10.1016/j.vac-cine.2015.06.012Loubet P, Kerneis S, Groh M, et al. Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency. Vaccine. 2015;33(31):3703-8. doi: 10.1016/j.vac-cine.2015.06.012Subesinghe S, Rutherford AI, Ibrahim F, et al. A large two-centre study in to rates of influenza and pneumococcal vaccination and infection burden in rheumatoid arthritis in the UK. BMC Musculoskelet Disord. 2016;17:322. doi: 10.1186/s12891-016-1187-4Subesinghe S, Rutherford AI, Ibrahim F, et al. A large two-centre study in to rates of influenza and pneumococcal vaccination and infection burden in rheumatoid arthritis in the UK. BMC Musculoskelet Disord. 2016;17:322. doi: 10.1186/s12891-016-1187-4Ribeiro ACM, Guedes LKN, Moraes JCB, et al. Reduced sero-protection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. Ann Rheum Dis. 2011;70:2144-7. doi: 10.1136/ard.2011.152983Ribeiro ACM, Guedes LKN, Moraes JCB, et al. Reduced sero-protection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. Ann Rheum Dis. 2011;70:2144-7. doi: 10.1136/ard.2011.152983Наумцева МС, Белов БС, Александрова ЕН и др. Оценка иммуногенности и безопасности 23-валентной полисахаридной пневмококковой вакцины у больных ревматическими заболеваниями. Научно-практическая ревматология. 2015;53(6):586-90 doi: 10.14412/1995-4484-2015-586-590Naumtseva MS, Belov BS, Aleksandrova EN, et al. Assessment of the immunogenicity and safety of 23-valent polysaccharide pneumococcal vaccine in patients with rheumatic diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(6):586-90 (In Russ.). doi: 10.14412/1995-4484-2015-586-590Subesinghe S, Bechman K, Rutherford AI, et al. A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis. J Rheumatol. 2018;45(6):733-44. doi: 10.3899/jrheum.170710Subesinghe S, Bechman K, Rutherford AI, et al. A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis. J Rheumatol. 2018;45(6):733-44. doi: 10.3899/jrheum.170710Winthrop KL, Silverfield J, Racewicz A, et al. The effect of tofaci-tinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis. 2016;75(4):687-95. doi: 10.1136/annrheumdis-2014-207191Winthrop KL, Silverfield J, Racewicz A, et al. The effect of tofaci-tinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis. 2016;75(4):687-95. doi: 10.1136/annrheumdis-2014-207191Broyde A, Arad U, Madar-Balakirski N, et al. Longterm efficacy of an antipneumococcal polysaccharide vaccine among patients with autoimmune inflammatory rheumatic diseases. J Rheumatol. 2016;43(2):267-72. doi: 10.3899/jrheum.150397Broyde A, Arad U, Madar-Balakirski N, et al. Longterm efficacy of an antipneumococcal polysaccharide vaccine among patients with autoimmune inflammatory rheumatic diseases. J Rheumatol. 2016;43(2):267-72. doi: 10.3899/jrheum.150397Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309-18. doi: 10.1093/cid/cit816Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309-18. doi: 10.1093/cid/cit816Heijstek MW, van Gageldonk PG, Berbers GA, et al. Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study. Ann Rheum Dis. 2012;71(6):948-54. doi: 10.1136/annrheumdis-2011-200637Heijstek MW, van Gageldonk PG, Berbers GA, et al. Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study. Ann Rheum Dis. 2012;71(6):948-54. doi: 10.1136/annrheumdis-2011-200637Miyamoto M, Ono E, Barbosa C, et al. Vaccine antibodies and T- and B-cell interaction in juvenile systemic lupus erythematosus. Lupus. 2011;20(7):736-44. doi: 10.1177/0961203310397409Miyamoto M, Ono E, Barbosa C, et al. Vaccine antibodies and T- and B-cell interaction in juvenile systemic lupus erythematosus. Lupus. 2011;20(7):736-44. doi: 10.1177/0961203310397409Borte S, Liebert UG, Borte M, Sack U. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology (Oxford). 2009;48(2):144-8. doi: 10.1093/rheuma-tology/ken436Borte S, Liebert UG, Borte M, Sack U. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology (Oxford). 2009;48(2):144-8. doi: 10.1093/rheuma-tology/ken436Heijstek MW, Kamphuis S, Armbrust W, et al. Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial. JAMA. 2013;309(23):2449-56. doi: 10.1001/jama.2013.6768Heijstek MW, Kamphuis S, Armbrust W, et al. Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial. JAMA. 2013;309(23):2449-56. doi: 10.1001/jama.2013.6768Blumentals WA, Arreglado A, Napalkov P, Toovey S. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord. 2012;13:158. doi: 10.1186/1471-2474-13-158Blumentals WA, Arreglado A, Napalkov P, Toovey S. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord. 2012;13:158. doi: 10.1186/1471-2474-13-158Dirven L, Huizinga TW, Allaart CF. Risk factors for reported influenza and influenza-like symptoms in patients with rheumatoid arthritis. Scand J Rheumatol. 2012;41(5):359-65. doi: 10.3109/03009742.2012.670729Dirven L, Huizinga TW, Allaart CF. Risk factors for reported influenza and influenza-like symptoms in patients with rheumatoid arthritis. Scand J Rheumatol. 2012;41(5):359-65. doi: 10.3109/03009742.2012.670729Bello SL, Serafino L, Bonali C, et al. Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents. Reumatismo. 2012;64(5):299-306. doi: 10.4081/reumatismo.2012.299Bello SL, Serafino L, Bonali C, et al. Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents. Reumatismo. 2012;64(5):299-306. doi: 10.4081/reumatismo.2012.299Mohammad AJ, Segelmark M, Smith R, et al. Severe Infection in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. J Rheumatol. 2017;44(10):1468-75. doi: 10.3899/jrheum.160909Mohammad AJ, Segelmark M, Smith R, et al. Severe Infection in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. J Rheumatol. 2017;44(10):1468-75. doi: 10.3899/jrheum.160909Hak E, Nordin J, Wei F, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis. 2002;35(4):370-7. doi: 10.1086/341403Hak E, Nordin J, Wei F, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis. 2002;35(4):370-7. doi: 10.1086/341403Chang CC, Chang YS, Chen WS, et al. Effects of annual influenza vaccination on morbidity and mortality in patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study. Sci Rep. 2016;6:37817. doi: 10.1038/srep37817Chang CC, Chang YS, Chen WS, et al. Effects of annual influenza vaccination on morbidity and mortality in patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study. Sci Rep. 2016;6:37817. doi: 10.1038/srep37817Kobashigawa T, Nakajima A, Taniguchi A, et al. Vaccination against seasonal influenza is effective in Japanese patients with rheumatoid arthritis enrolled in a large observational cohort. Scand J Rheumatol. 2013;42(6):445-50. doi: 10.3109/03009742.2013.788733Kobashigawa T, Nakajima A, Taniguchi A, et al. Vaccination against seasonal influenza is effective in Japanese patients with rheumatoid arthritis enrolled in a large observational cohort. Scand J Rheumatol. 2013;42(6):445-50. doi: 10.3109/03009742.2013.788733Van Assen S, Holvast A, Benne CA, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010;62(1):75-81. doi: 10.1002/art.25033Van Assen S, Holvast A, Benne CA, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010;62(1):75-81. doi: 10.1002/art.25033Arad U, Tzadok S, Amir S, et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine. 2011;29(8):1643-8. doi: 10.1016/j.vaccine.2010.12.072Arad U, Tzadok S, Amir S, et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine. 2011;29(8):1643-8. doi: 10.1016/j.vaccine.2010.12.072Park JK, Lee YJ, Shin K, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2018;77(6):898-904. doi: 10.1136/annrheumdis-2018-213222Park JK, Lee YJ, Shin K, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2018;77(6):898-904. doi: 10.1136/annrheumdis-2018-213222Campos LM, Silva CA, Aikawa NE, et al. High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2013;65(7):1121-7. doi: 10.1002/acr.21948Campos LM, Silva CA, Aikawa NE, et al. High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2013;65(7):1121-7. doi: 10.1002/acr.21948Gabay C, Bel M, Combescure C, et al. Impact of synthetic and biologic disease modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum. 2011;63:1486-96. doi: 10.1002/art.30325Gabay C, Bel M, Combescure C, et al. Impact of synthetic and biologic disease modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum. 2011;63:1486-96. doi: 10.1002/art.30325Milanetti F, Germano V, Nisini R, et al. Safety and immunogenicity of co-administered MF59-adjuvanted 2009 pandemic and plain 2009-10 seasonal influenza vaccines in rheumatoid arthritis patients on biologicals. Clin Exp Immunol. 2014;177(1):287-94. doi: 10.1111/cei.12292Milanetti F, Germano V, Nisini R, et al. Safety and immunogenicity of co-administered MF59-adjuvanted 2009 pandemic and plain 2009-10 seasonal influenza vaccines in rheumatoid arthritis patients on biologicals. Clin Exp Immunol. 2014;177(1):287-94. doi: 10.1111/cei.12292Adler S, Krivine A, Weix J, et al. Protective effect of A/H1N1 vaccination in immunemediated disease — a prospectively controlled vaccination study. Rheumatology. 2012;51:695-700. doi: 10.1093/rheumatology/ker389Adler S, Krivine A, Weix J, et al. Protective effect of A/H1N1 vaccination in immunemediated disease — a prospectively controlled vaccination study. Rheumatology. 2012;51:695-700. doi: 10.1093/rheumatology/ker389Kapetanovic MC, Kristensen LE, Saxne T, et al. Impact of antirheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Res Ther. 2014;16(1):R2. doi: 10.1186/ar4427Kapetanovic MC, Kristensen LE, Saxne T, et al. Impact of antirheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Res Ther. 2014;16(1):R2. doi: 10.1186/ar4427Elkayam O, Amir S, Mendelson E, et al. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res (Hoboken). 2011;63(7):1062-7. doi: 10.1002/acr.20465Elkayam O, Amir S, Mendelson E, et al. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res (Hoboken). 2011;63(7):1062-7. doi: 10.1002/acr.20465Miossi R, Fuller R, Moraes JC, et al. Immunogenicity of influenza H1N1 vaccination in mixed connective tissue disease: effect of disease and therapy. Clinics (Sao Paulo). 2013;68(2):129-34. doi: 10.6061/clinics/2013(02)0A02Miossi R, Fuller R, Moraes JC, et al. Immunogenicity of influenza H1N1 vaccination in mixed connective tissue disease: effect of disease and therapy. Clinics (Sao Paulo). 2013;68(2):129-34. doi: 10.6061/clinics/2013(02)0A02Curtis JR, Yang S, Patkar NM, et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66(7):990-7. doi: 10.1002/acr.22281Curtis JR, Yang S, Patkar NM, et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66(7):990-7. doi: 10.1002/acr.22281Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum InfectDis. 2014;1(1):ofu024. doi: 10.1093/ofid/ofu024Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum InfectDis. 2014;1(1):ofu024. doi: 10.1093/ofid/ofu024Wotton CJ, Goldacre MJ. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-medi-ated diseases: record linkage cohort analyses. J Epidemiol Commun Health. 2012;66(12):1177-81. doi: 10.1136/jech-2011-200168Wotton CJ, Goldacre MJ. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-medi-ated diseases: record linkage cohort analyses. J Epidemiol Commun Health. 2012;66(12):1177-81. doi: 10.1136/jech-2011-200168Coulson E, Saravanan V, Hamilton J, et al. Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate. Ann Rheum Dis. 2011;70(7):1289-91. doi: 10.1136/ard.2010.144451Coulson E, Saravanan V, Hamilton J, et al. Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate. Ann Rheum Dis. 2011;70(7):1289-91. doi: 10.1136/ard.2010.144451Tsuru T, Terao K, Murakami M, et al. Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab. Mod Rheumatol. 2014;24:511-6. doi: 10.3109/14397595.2013.843743Tsuru T, Terao K, Murakami M, et al. Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab. Mod Rheumatol. 2014;24:511-6. doi: 10.3109/14397595.2013.843743Migita K, Akeda Y, Akazawa M, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus. Arthritis Res Ther. 2015;17:149. doi: 10.1186/s13075-015-0662-xMigita K, Akeda Y, Akazawa M, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus. Arthritis Res Ther. 2015;17:149. doi: 10.1186/s13075-015-0662-xBingham CO 3rd, Rizzo W, Kivitz A, et al. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis. 2015;74(5):818-22. doi: 10.1136/annrheumdis-2013-204427Bingham CO 3rd, Rizzo W, Kivitz A, et al. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis. 2015;74(5):818-22. doi: 10.1136/annrheumdis-2013-204427Rezende RPV, Ribeiro FM, Albuquerque EMN, et al. Immunogenicity of pneumococcal polysaccharide vaccine in adult systemic lupus erythematosus patients undergoing immunosuppressive treatment. Lupus. 2016;25:1254-9. doi: 10.1177/0961203316636472Rezende RPV, Ribeiro FM, Albuquerque EMN, et al. Immunogenicity of pneumococcal polysaccharide vaccine in adult systemic lupus erythematosus patients undergoing immunosuppressive treatment. Lupus. 2016;25:1254-9. doi: 10.1177/0961203316636472Белов БС. Вакцинация при ревматических заболеваниях: союзник или противник? Научно-практическая ревматология. 2018;56(4):401-4. doi: 10.14412/1995-4484-2018-401-404Belov BS. Vaccination in rheumatic diseases: an ally or an enemy? Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(4):401-4 (In Russ.). doi: 10.14412/1995-4484-2018-401-404Тарасова ГМ, Белов БС, Буханова ДВ и др. Изучение иммуногенности и безопасности 23-валентной полисахаридной пневмококковой вакцины у больных системной красной волчанкой. Научно-практическая ревматология, 2018;56(4):433-8. doi: 10.14412/1995-4484-2018-433-438Tarasova GM, Belov BS, Bukhanova DV, et al. Investigation of immunogenicity and safety of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(4):433-8 (In Russ.). doi: 10.14412/1995-4484-2018-433-438Tarasova G, Belov B, Bukhanova D, et al. Use of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus: the relationship of immunogenicity with therapy. Ann Rheum Dis. 2019;78 Suppl 2:785-6. doi: 10.1136/annrheumdis-2019-eular.3646Tarasova G, Belov B, Bukhanova D, et al. Use of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus: the relationship of immunogenicity with therapy. Ann Rheum Dis. 2019;78 Suppl 2:785-6. doi: 10.1136/annrheumdis-2019-eular.3646Bukhanova D, Belov B, Tarasova G, et al. Immunogenicity and safety of 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results from 5-year follow up. Ann Rheum Dis. 2019;78 Suppl 2:336. doi: 10.1136/annrheumdis-2019-eular.3173Bukhanova D, Belov B, Tarasova G, et al. Immunogenicity and safety of 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results from 5-year follow up. Ann Rheum Dis. 2019;78 Suppl 2:336. doi: 10.1136/annrheumdis-2019-eular.3173Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61:816-9. doi: 10.1111/ajt.12073Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61:816-9. doi: 10.1111/ajt.12073Чучалин АГ, Брико НИ, Авдеев СН и др. Федеральные клинические рекомендации по вакцинопрофилактике пневмококковой инфекции у взрослых. Пульмонология. 2019;29(1):19-34 doi: 10.18093/0869-0189-2019-29-1-19-34Chuchalin AG, Briko NI, Avdeev SN, et al. Federal Clinical Guidelines on Preventive Vaccination Against Pneumococcal infections in Adults. Pul’monologiya = Russian Pulmonology. 2019;29(1):19-34 (In Russ.). doi: 10.18093/0869-0189-2019-29-1-19-34Crnkic Kapetanovic M, Saxne T, Truedsson L, Geborek P. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs. Arthritis Res Ther. 2013 Jan 4;15(1):R1. doi: 10.1186/ar4127Crnkic Kapetanovic M, Saxne T, Truedsson L, Geborek P. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs. Arthritis Res Ther. 2013 Jan 4;15(1):R1. doi: 10.1186/ar4127Kapetanovic MC, Nagel J, Nordstrom I, et al. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine. Vaccine. 2017 Feb 7;35(6):903-8. doi: 10.1016/j.vac-cine.2016.12.068Kapetanovic MC, Nagel J, Nordstrom I, et al. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine. Vaccine. 2017 Feb 7;35(6):903-8. doi: 10.1016/j.vac-cine.2016.12.068Salinas GF, De Rycke L, Barendregt B, et al. Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann Rheum Dis. 2013;72:1037-43. doi: 10.1136/annrheumdis-2011-201270Salinas GF, De Rycke L, Barendregt B, et al. Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann Rheum Dis. 2013;72:1037-43. doi: 10.1136/annrheumdis-2011-201270Migita K, Akeda Y, Akazawa M, et al. Opsonic and antibody responses to pneumococcal polysaccharide in rheumatoid arthritis patients receiving golimumab plus methotrexate. Medicine Baltimore. 2015;94(52):e2184. doi: 10.1097/MD.0000000000002184Migita K, Akeda Y, Akazawa M, et al. Opsonic and antibody responses to pneumococcal polysaccharide in rheumatoid arthritis patients receiving golimumab plus methotrexate. Medicine Baltimore. 2015;94(52):e2184. doi: 10.1097/MD.0000000000002184Наумцева МС, Белов БС, Александрова ЕИ и др. Иммуногенность и безопасность 23-валентной полисахаридной пневмококковой вакцины у больных ревматоидным артритом: результаты двухлетнего наблюдения. Научно-практическая ревматология. 2016;54(6):674-80. doi: 10.14412/1995-4484-2016-674-680Naumtseva MS, Belov BS, Aleksandrova EN, et al. Immunogenicity and safety of 23-valent polysaccharide pneumococcal vaccine in patients with rheumatoid arthritis: Results of a two-year follow-up study. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(6):674-80 (In Russ.). doi: 10.14412/1995-4484-2016-674-680Grabar S, Groh M, Bahuaud M, et al. Pneumococcal vaccination in patients with systemic lupus erythematosus: A multicenter placebo-controlled randomized double-blind study. Vaccine. 2017;35(37):4877-85. doi: 10.1016/j.vaccine.2017.07.094Grabar S, Groh M, Bahuaud M, et al. Pneumococcal vaccination in patients with systemic lupus erythematosus: A multicenter placebo-controlled randomized double-blind study. Vaccine. 2017;35(37):4877-85. doi: 10.1016/j.vaccine.2017.07.094Nived P, Nagel J, Saxne T, et al. Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy. Vaccine. 2017 Jun 22;35(29):3639-46. doi: 10.1016/j.vaccine.2017.05.044Nived P, Nagel J, Saxne T, et al. Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy. Vaccine. 2017 Jun 22;35(29):3639-46. doi: 10.1016/j.vaccine.2017.05.044Devey ME, Bleasdale K, Isenberg DA. Antibody affinity and IgG subclass of responses to tetanus toxoid in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol. 1987;68(3):562-9.Devey ME, Bleasdale K, Isenberg DA. Antibody affinity and IgG subclass of responses to tetanus toxoid in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol. 1987;68(3):562-9.Battafarano DF, Battafarano NJ, Larsen L, et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum. 1998;41(10):1828-34. doi: 10.1002/1529-0131(199810)41:10<1828::AID-ART15>3.0.CO;2-TBattafarano DF, Battafarano NJ, Larsen L, et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum. 1998;41(10):1828-34. doi: 10.1002/1529-0131(199810)41:10<1828::AID-ART15>3.0.CO;2-TBingham CO 3rd, Winthrop KL, Yang L, et al. BAFF inhibition does not significantly impair immunization responses in patients with rheumatoid arthritis. Arthritis Res Ther. 2015;17:347. doi: 10.1186/s13075-015-0867-zBingham CO 3rd, Winthrop KL, Yang L, et al. BAFF inhibition does not significantly impair immunization responses in patients with rheumatoid arthritis. Arthritis Res Ther. 2015;17:347. doi: 10.1186/s13075-015-0867-zBingham CO, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010;62:64-74. doi: 10.1002/art.25034Bingham CO, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010;62:64-74. doi: 10.1002/art.25034Askling HH, Rombo L, van Vollenhoven R, et al. Hepatitis a vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, openlabel, multi-centre study. Travel Med Infect Dis. 2014;12:134-42. doi: 10.1016/j.tmaid.2014.01.005Askling HH, Rombo L, van Vollenhoven R, et al. Hepatitis a vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, openlabel, multi-centre study. Travel Med Infect Dis. 2014;12:134-42. doi: 10.1016/j.tmaid.2014.01.005Van den Bijllaardt W, Siers HM, Timmerman-Kok C, et al. Seroprotection after hepatitis A vaccination in patients with drug-induced immunosuppression. J Travel Med. 2013;20:278-82. doi: 10.1111/jtm.12050Van den Bijllaardt W, Siers HM, Timmerman-Kok C, et al. Seroprotection after hepatitis A vaccination in patients with drug-induced immunosuppression. J Travel Med. 2013;20:278-82. doi: 10.1111/jtm.12050Furer V, Rondaan C, Heijstek M, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019;5(2):e001041. doi: 10.1136/rmdopen-2019-001041Furer V, Rondaan C, Heijstek M, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019;5(2):e001041. doi: 10.1136/rmdopen-2019-001041Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308:43-9. doi: 10.1001/jama.2012.7304Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308:43-9. doi: 10.1001/jama.2012.7304Yun H, Xie F, Baddley JW, et al. Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases. J Rheumatol. 2017;44(7):1083-7. doi: 10.3899/jrheum.160685Yun H, Xie F, Baddley JW, et al. Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases. J Rheumatol. 2017;44(7):1083-7. doi: 10.3899/jrheum.160685Lyrio LD, Grassi MF, Santana IU, et al. Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus. Rheumatol Int. 2013;33(2):335-40. doi: 10.1007/s00296-012-2426-0Lyrio LD, Grassi MF, Santana IU, et al. Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus. Rheumatol Int. 2013;33(2):335-40. doi: 10.1007/s00296-012-2426-0Mendoza-Pinto C, Garcia-Carrasco M, Vallejo-Ruiz V, et al. The impact of glucocorticoids and anti-CD20 therapy on cervical human papillomavirus infection risk in women with systemic lupus erythematosus. Clinics. 2013;68:1475-80. doi: 10.6061/clin-ics/2013(12)01Mendoza-Pinto C, Garcia-Carrasco M, Vallejo-Ruiz V, et al. The impact of glucocorticoids and anti-CD20 therapy on cervical human papillomavirus infection risk in women with systemic lupus erythematosus. Clinics. 2013;68:1475-80. doi: 10.6061/clin-ics/2013(12)01Klumb EM, Pinto AC, Jesus GR, et al. Are women with lupus at higher risk of HPV infection? Lupus. 2010;19(13):1485-91. doi: 10.1177/0961203310372952Klumb EM, Pinto AC, Jesus GR, et al. Are women with lupus at higher risk of HPV infection? Lupus. 2010;19(13):1485-91. doi: 10.1177/0961203310372952Mendoza-Pinto C, Garcia-Carrasco M, Vallejo-Ruiz V, et al. Incidence of cervical human papillomavirus infection in systemic lupus erythematosus women. Lupus. 2017;26:944-51. doi: 10.1177/0961203316686708Mendoza-Pinto C, Garcia-Carrasco M, Vallejo-Ruiz V, et al. Incidence of cervical human papillomavirus infection in systemic lupus erythematosus women. Lupus. 2017;26:944-51. doi: 10.1177/0961203316686708Mok CC, Ho LY, Fong LS, et al. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 2013;72:659-64. doi: 10.1136/annrheumdis-2012-201393Mok CC, Ho LY, Fong LS, et al. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 2013;72:659-64. doi: 10.1136/annrheumdis-2012-201393Dhar JP, Essenmacher L, Dhar R, et al. The safety and immunogenicity of quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus. Vaccine. 2017;35:2642-6. doi: 10.1016/j.vac-cine.2017.04.001Dhar JP, Essenmacher L, Dhar R, et al. The safety and immunogenicity of quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus. Vaccine. 2017;35:2642-6. doi: 10.1016/j.vac-cine.2017.04.001Mok CC, Ho LY, To CH. Long-term immunogenicity of a quadrivalent human papillomavirus vaccine in systemic lupus erythematosus. Vaccine. 2018;36:3301-7. doi.org/10.1016/j.vac-cine.2018.04.056Mok CC, Ho LY, To CH. Long-term immunogenicity of a quadrivalent human papillomavirus vaccine in systemic lupus erythematosus. Vaccine. 2018;36:3301-7. doi.org/10.1016/j.vac-cine.2018.04.056Gro nlund O, Herweijer E, Sundstrom K, Arnheim-Dahlstrom L. Incidence of new-onset autoimmune disease in girls and women with pre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study. J Intern Med. 2016;280(6):618-26. doi: 10.1111/joim.12535Gro nlund O, Herweijer E, Sundstrom K, Arnheim-Dahlstrom L. Incidence of new-onset autoimmune disease in girls and women with pre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study. J Intern Med. 2016;280(6):618-26. doi: 10.1111/joim.12535Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology. 2016;151:110-9. doi: 10.1053/j.gastro.2016.04.002Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology. 2016;151:110-9. doi: 10.1053/j.gastro.2016.04.002Mariette X, Forger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228-33. doi: 10.1136/annrheumdis-2017-212196Mariette X, Forger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228-33. doi: 10.1136/annrheumdis-2017-212196Fo rger F, Zbinden A, Villiger PM. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients. Joint Bone Spine. 2016;83(3):341-3. doi: 10.1016/j.jbspin.2015.07.004Fo rger F, Zbinden A, Villiger PM. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients. Joint Bone Spine. 2016;83(3):341-3. doi: 10.1016/j.jbspin.2015.07.004Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:286-92,quiz e24. doi: 10.1016/j.cgh.2012.11.011Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:286-92,quiz e24. doi: 10.1016/j.cgh.2012.11.011Zelinkova Z, de Haar C, de Ridder L, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther. 2011;33:1053-8. doi: 10.1111/j.1365-2036.2011.04617.xZelinkova Z, de Haar C, de Ridder L, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther. 2011;33:1053-8. doi: 10.1111/j.1365-2036.2011.04617.xBerthelsen BG, Fjeldsoe-Nielsen H, Nielsen CT, et al. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology. 2010;49:2225-7. doi: 10.1093/rheumatology/keq185Berthelsen BG, Fjeldsoe-Nielsen H, Nielsen CT, et al. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology. 2010;49:2225-7. doi: 10.1093/rheumatology/keq185Go testam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795-810. doi: 10.1136/annrheumdis-2015-208840Go testam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795-810. doi: 10.1136/annrheumdis-2015-208840

The authors declare that there are no conflicts of interest present.